SK-MEL-29 is one of a series of melanoma cell lines established from patient-derived tumor samples. This cell line expresses mutant B-Raf (V600E) and wildtype N-Ras.
This cell line was established in 1975 from a recurrent melanoma at the apex of the left axilla of a 19-year-old Caucasian male.
- Lloyd J. Old, MD, former William E. Snee Chair in Cancer Immunology, Memorial Sloan Kettering; former Director, New York Branch, Ludwig Institute for Cancer Research
- Toshitada Takahashi, MD, formerly at Sloan Kettering Institute, Memorial Sloan Kettering
- Carey TE et al. (1976) Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proceedings of the National Academy of Sciences 73: 3278-3282 (Pubmed ID: 1067619)
- Lau YS et al. (2006) Malignant melanoma and bone resorption. British Journal of Cancer 94(10): 1496-1503 (PubMed ID: 16641914)
- Xing F et al. (2012) Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E) BRAF. Oncogene 31(4): 446-457 (Pubmed ID: 21725359)
This cell line may be licensed nonexclusively for research or commercial purposes.
- For licensing requests: Alexandra Buga, MBA, Business Development Analyst, Office of Technology Development, MSK, 646-888-1078, [email protected]
- For non-licensing requests from academic-research institutions: Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354, [email protected]